Measurable disease by RECIST v.
Measurable disease by RECIST . (Phase  only)
Subject in Phase  only: must have measurable disease per RECIST ..
. Measurable disease per RECIST v. and irRECIST;
Measurable disease per RECIST ..
Measurable disease per RECIST ..
Measurable disease by RECIST .
Measurable disease via RECIST
Measurable disease by RECIST v.
One site of measurable disease by RECIST .
Participants must have measurable disease (RECIST .)
Baseline measurable disease as measured by RECIST v. .
Has measurable disease per RECIST . as assessed by the investigator/radiology
Measurable disease per RECIST v.
Presence of measurable disease per RECIST v..
Has measurable disease per RECIST . as determined by investigator
Phase a: measurable or non-measurable disease per RECIST v ..
Phase b: measurable disease per RECIST v . (subjects with non-measurable disease are not eligible for Phase b).
Measurable disease per RECIST v.
Measurable disease per RECIST v. by radiographic techniques
Radiographically measurable disease by RECIST v.
Measurable disease by RECIST .
PART II: Patients must have measurable disease, per RECIST .
Measurable disease as outlined in RECIST .
Patients must have metastatic disease, per RECIST . for the evaluation of measurable disease.
Measurable disease per RECIST .
Measurable disease by RECIST .
COHORT : ENDOMETRIAL CANCER: Patients must have measurable disease, per RECIST .
Presence of measurable disease by RECIST .
Presence of measurable disease per RECIST v..
Measurable disease by RECIST
For disease-specific cohort participants: measurable disease per RECIST v. .
Phase : Participants must have measurable disease as per RECIST ..
Have measurable disease per RECIST v., assessed within  weeks prior to study entry
Measurable disease (RECIST .)
Patients must have measurable soft tissue disease per RECIST .
Measurable disease per RECIST .
Measurable disease by RECIST .
Measurable disease per RECIST v..
Measurable disease per RECIST . (primary or metastases)
Measurable disease by RECIST .
Radiographically measurable disease per RECIST .
Disease must be measurable by RECIST .
Patients must have measurable disease as per RECIST v.
Radiographically measurable per RECIST v..
Has measurable disease per RECIST . as assessed by the local site investigator/radiology
Measurable disease per RECIST . as assessed by the local site investigator/radiology.
Measurable Disease by RECIST v.
Measurable disease per RECIST v. for patients with solid malignancies.
Measurable disease by RECIST . guidelines
Participants must have measurable disease by RECIST .
Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by computed tomography (CT) scan; examinations for assessment of measurable disease must have been completed within  days prior to registration; examinations for assessment of non-measurable disease must have been performed within  days prior to registration; all disease must be assessed and documented on the RECIST . and Modified RECIST Baseline Tumor Assessment Form
Measurable disease as per RECIST .. Subject must have extracranial metastasis as measurable disease
Measurable lesions by RECIST v.
Measurable disease per RECIST v.
Measurable Disease per RECIST . as determined by the Investigator
Measurable disease by RECIST
Has measurable disease per RECIST . as assessed by BICR.
Has measurable disease per RECIST . as assessed by the investigator/site radiologist.
Measurable disease per RECIST . guidelines.
Measurable disease per RECIST v.
Measurable disease per RECIST v.
Measurable disease per RECIST v.
Disease must be measurable by RECIST .
Patients must not have measurable progressive disease (RECIST .)
Measurable disease per RECIST v. (see Appendix )
Presence of measurable disease per RECIST v..
Cancer antigen- (CA-) only disease without RECIST . measurable disease
Does not have measurable disease per RECIST .
Disease must be measurable by RECIST .
Measurable disease per RECIST v..
Evidence of measurable disease per RECIST .
Radiographically measurable disease acc. to RECIST .
Measurable disease as per RECIST v.
Presence of measurable lesions (RECIST V.)
Patient has measurable disease by (RECIST).
Has measurable disease per RECIST . as determined by the local site investigator/radiology assessment
Patients must have RECIST v. measurable disease
Measurable disease per RECIST . as determined by the investigator.
Measurable disease as per RECIST v. ..
Presence of measurable disease per RECIST v.
Measurable disease as per RECIST .
Measurable disease per RECIST v. (see Appendix )
Measurable disease per RECIST v.
Measurable disease by RECIST .
Measurable disease per RECIST v.
Measurable disease as per RECIST v.
Measurable disease per RECIST v.
Measurable disease per RECIST . guidelines. Cohort  may include up to  subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v.
At least  site of disease measurable by RECIST ver.
Measurable disease that can be monitored per RECIST throughout the course of study participation.
Patient must have either measurable disease by RECIST . or bone lesions in absence of measurable disease.
Measurable disease (per RECIST v.) prior to the start of first-line chemotherapy
Measurable disease by RECIST .
Measurable disease as per RECIST .
Disease that is measurable per RECIST v.
Measurable disease per RECIST .
ECOG performance status  or  . Measurable disease per RECIST v.
Measurable disease as per RECIST v.
Measurable disease as per RECIST ..
Patient has progressive and measurable disease as per RECIST .. or other appropriate hematological guidelines.
Patient has progressive and measurable disease as per RECIST . or other appropriate hematological guidelines.
Measurable disease per RECIST v..
Measurable disease per RECIST .
Measurable disease by RECIST
At least one measurable disease site per RECIST v..
Disease that is measurable per modified RECIST v.
Measurable disease (by RECIST .)
Measurable disease by RECIST . with PCWG modifications
Measurable disease per RECIST v .
Measurable Disease per RECIST .
Measurable disease by RECIST v.
Measurable disease per RECIST v.
Measurable disease as determined by RECIST .
Measurable disease at presentation with disease measurable by RECIST required in the phase II cohort
Measurable disease by RECIST .
Have measurable disease per RECIST v...
Measurable disease per RECIST v.
Evidence of measurable disease by RECIST .
Measurable disease by RECIST .
With the exception of patients with non-measurable neuroblastoma patients must have measurable disease as per RECIST .
Presence of measurable (by RECIST v.) and active extracranial disease will be excluded; patients with measurable extra cranial disease by RECIST v. will be eligible to enroll if sites of disease are stable and not considered to be active after discussion with the sponsor
Patients must have measurable disease per RECIST v. ..
